DDInter556 DDInter1180
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Methscopolamine is a quaternary ammonium derivative of scopolamine and antagonist at muscarininc (mACh) receptors. Methscopolamine bromide is the most common form of the active ingredient in oral pharmaceutical products. The oral tablets are used as an adjunct therapy for the treatment of peptic ulcer and is shown to be effective in decreasing the rate of recurrence of peptic ulcers as well as preventing complications.
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Dihydrocodeine {u} (Compound) binds {v} (Gene) CYP2D6
Dihydrocodeine {u} (Compound) is included by {v} (Pharmacologic Class) Full Opioid Agonists
Dihydrocodeine {u} (Compound) causes {v} (Side Effect) Somnolence
Dihydrocodeine (Compound) resembles Galantamine (Compound)
Dihydrocodeine (Compound) resembles Oxymorphone (Compound)
Dihydrocodeine (Compound) binds CYP2D6 (Gene)
Dihydrocodeine (Compound) is included by Full Opioid Agonists (Pharmacologic Class)
Dihydrocodeine (Compound) causes Somnolence (Side Effect)